ABT 652

Drug Profile

ABT 652

Alternative Names: ABT-652

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Analgesics; Sleep disorder therapies
  • Mechanism of Action Histamine H3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Musculoskeletal pain; Sleep disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 26 Jul 2012 Profile reviewed, separated combination therapy trial in ph table, changed Neur pain to Diab neur, added formulation for Diab pain, updated Inthought scores
  • 26 Jul 2012 Abbott plans phase IIb trials for Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top